EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence
![](https://researchstudies.cuanschutz.edu/Content/images/study-category-images/cancer.jpg)
Details
Age
Adult
Locations
Highlands Ranch Hospital
Lone Tree Medical Center
University of Colorado Hospital
Principal Investigator
![Photograph of Elena Shagisultanova](https://som.ucdenver.edu/FIMS/Content/faculty/23576/CU-Doctors-23576.jpg)
Elena Shagisultanova
Study ID
Protocol Number: 22-1554
More information available at ClinicalTrials.gov: NCT05514054
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers